These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36869388)

  • 1. Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study.
    Meenks SD; Punt N; le Noble JLML; Foudraine NA; Neef K; Janssen PKC
    Crit Care; 2023 Mar; 27(1):82. PubMed ID: 36869388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High unbound flucloxacillin fraction in critically ill patients.
    Wallenburg E; Ter Heine R; de Lange DW; van Leeuwen H; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Gieling EM; de Maat MM; Frenzel T; Brüggemann RJ
    J Antimicrob Chemother; 2021 Nov; 76(12):3220-3228. PubMed ID: 34463730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.
    Jager NGL; van Hest RM; Xie J; Wong G; Ulldemolins M; Brüggemann RJM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2641-2649. PubMed ID: 32443147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen.
    Wilkes S; van Berlo I; Ten Oever J; Jansman F; Ter Heine R
    Int J Antimicrob Agents; 2019 Mar; 53(3):310-317. PubMed ID: 30472288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs.
    Moser S; Rehm S; Guertler N; Hinic V; Dräger S; Bassetti S; Rentsch KM; Sendi P; Osthoff M
    J Antimicrob Chemother; 2021 Jun; 76(7):1845-1854. PubMed ID: 33860325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
    Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
    Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
    Drennan PG; Green JK; Gardiner SJ; Metcalf SCL; Kirkpatrick CMJ; Everts RJ; Zhang M; Chambers ST
    Br J Clin Pharmacol; 2021 Dec; 87(12):4681-4690. PubMed ID: 33963595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
    Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of pharmacological target attainment with flucloxacillin and cefazolin in invasive methicillin-susceptible Staphylococcus aureus infection: a prospective cohort study in hospitalized patients.
    Campbell PO; Chin PKL; Dalton SC; Metcalf SCL; Douglas NM; Chambers ST
    Int J Antimicrob Agents; 2023 Jan; 61(1):106695. PubMed ID: 36464153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue- Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations.
    Öbrink-Hansen K; Pham AD; Bue M; Hanberg P; Bendtsen M; Slater J; Friberg LE; Thorsted A; Stilling M
    Pharm Res; 2022 Jul; 39(7):1633-1643. PubMed ID: 35233728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.